Fundraising Fox

InSitu Biologics

Oakdale, US · Founded 2017 · Delaware corporation

Biotech

Founders & leadership

BT
Bill TaylorExecutive
DH
Daniel HalpernExecutive
SK
Sandi KlemannExecutive
JK
James KnappNamed on SEC filing
JS
Jim SegermarkNamed on SEC filing

Board

RW
Robert WilsonBoard director
GV
Greg Van GuilderBoard director
IS
Ivan ShawBoard director

Reported raises · per SEC filings

Form D private placements

$13.2M disclosed across 4 of 6 rounds · 2017–2026

▶$1.3MraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel HalpernExecutive Officer, Director
  • Bill TaylorExecutive Officer
  • Sandi KlemannExecutive Officer
  • Robert WilsonDirector
  • Greg Van GuilderDirector
  • Ivan ShawDirector
Offering amount
$2.5M
Amount sold
$1.3M
Minimum investment
$2.5M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedDec 2025 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill TaylorExecutive Officer
  • Robert WilsonDirector
  • Greg Van GuilderDirector
  • Daniel HalpernExecutive Officer, Director
  • Sandi KlemannExecutive Officer
  • Ivan ShawDirector
Offering amount
$8M
Amount sold
$4M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert WilsonDirector
  • James KnappDirector
  • Kevin BassettExecutive Officer, Director
  • Buzz BensonDirector
  • Mark ErethExecutive Officer
  • Kay WarnottExecutive Officer
  • Kevin BarrettExecutive Officer
  • Andy LaFrenceDirector
  • Bill TaylorExecutive Officer
Offering amount
$3M
Amount sold
$3M
Minimum investment
$3M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedFeb 2021 · 22 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Kevin BassettExecutive Officer, Director
  • Bill TaylorExecutive Officer
  • Kay WarnottExecutive Officer
  • Kevin BarrettExecutive Officer
  • James KnappDirector
  • Robert WilsonDirector
  • Andy LaFrenceDirector
  • Buzz BensonDirector
Offering amount
$5.5M
Amount sold
$5M
Minimum investment
$50K
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1MofferedMar 2018 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • James KnappExecutive Officer
  • Jim SegermarkExecutive Officer
Offering amount
$1M
Minimum investment
$50K
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1MofferedNov 2017 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Jim SegermarkExecutive Officer
  • James KnappExecutive Officer
Offering amount
$1M
Minimum investment
$50K
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

InSitu Biologics | Manhattan Street Capitalmanhattanstreetcapital.com · Aug 2025InSitu Biologics Shares Latest Investigational Work at ASRA Meeting - November 18, 2022 - BioSpacebiospace.com · Nov 2022InSitu Biologics: Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials - BioSpacebiospace.com · Dec 2018InSitu Biologics Raises Over $2M in Funding - FinSMEsfinsmes.com · Dec 2018Non-opiate Painkilling Gel Maker InSitu Biologics Looking to Raise $1M | Twin Cities Businesstcbmag.com · Dec 2017

Frequently asked questions

How much funding has InSitu Biologics raised?
InSitu Biologics has disclosed $13.2M raised across 4 of its 6 known rounds.
Where is InSitu Biologics headquartered?
InSitu Biologics is headquartered in Oakdale, US.